Because surfactant protein (SP) mRNA levels in rat fetuses are increased by maternal dexamethasone (dex) treatment and decreased in streptozotocin-induced diabetic (STZ-DB) pregnancy, we investigated the in vivo effects of dex on SP gene expression in STZ-DB pregnancy. 2) a 2-3-fold increase in SP-C mRNA levels was observed in response to dex in d 18 and 20 fetuses; 3) the increase in transcription of SP-A and SP-B in d 20 fetuses after dex is 68 and 60%, respectively, of the increase in their mRNA levels whereas in STZ-DB, the decrease in transcription compared with mRNA levels is 3.67-fold for SP-A and 2.42 fold SP-B; and 4) changes in SP-C transcription in either in vivo model, dex-treated or STZ-DB, correspond well with changes in mRNA levels. Together, these findings indicate that dex can enhance SP expression in STZ-DB immature lungs and support differential regulation of fetal SP genes in the models studied. (Pediatr Res 38: 870-877, 1995)
ture (3, 4) , function (5) (6) (7) (8) , and metabolism (9) of surfactant. The role of SP-D in the function of surfactant is not yet defined (10) .
Deficiency of pulmonary surfactant in prematurely born infants suggests lung immaturity. In humans, the lecithin: sphingomyelin ratio of 2 2 and the presence of phosphatidylglycerol in amniotic fluid (1 1, 12) suggests fetal lung maturity. However, the infants in full term diabetic pregnancies are at increased risk of developing RDS, despite normal lecithin: sphingomyelin ratio of 2 2 (13) (14) (15) . Some reports have shown that the level of SP-A is reduced in amniotic fluid of pregnant diabetic women (16, 17) , suggesting that decreased SP-A contributes to the increased incidence of RDS in infants of diabetic mothers. Comparable studies regarding the levels of SP-B and SP-C in amniotic fluid have not been reported. On the other hand, administration of glucocorticoids to pregnant women can increase fetal surfactant production and has been used clinically to prevent RDS in preterm infants (18, 19) .
Glucocorticoids are shown to affect the expression of a small
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number of proteins in lung (20, 21) , and some of these proteins
Supported by the National Institutes of Health, R 0 1 HL38288 (J.F.), SCOR 5P50HL46488 (J.B.W.), and the American Heart Association, Pennsylvania Affiliate are lung-s~ecific (21 dose-dependent manner, suggesting that regulation of SP-A is a complex process and that the mechanism is not completely conserved among species (22) (23) (24) (25) . However, the effect of dex on rat SP-A expression is found to be stimulatory both in vivo (26) (27) (28) (29) and in vitro (25) . In contrast to SP-A, all studies have demonstrated a stimulatory effect of glucocorticoids on SP-B and SP-C mRNA levels (28) (29) (30) (31) . Furthermore, we have also shown that transcription of SP-C is increased in dex-treated explants, (31) but no in vivo work has been reported. The mRNA levels of SP-D in rats also increase in response to glucocorticoid treatment, both in vitro and in vivo (32, 33) . Similarly, SP-A, SP-B, and SP-C mRNA levels also increase developmentally during fetal life (28, 34, 35) . On the other hand, the levels of surfactant proteins (SP-A, SP-B) and the levels of SP mRNAs (SP-A, SP-B, SP-C) in rats are reduced (36, 37) in fetuses of STZ-DB pregnancy. These observations together suggest that a pretranslational event is involved in the regulation of SP gene expression in the two (STZ-DB and dex treatment) in vivo rat models. However, the mechanism by which dex and diabetes exert their effects in these models is not known.
In this report we have addressed two questions: I ) whether maternal dex treatment can enhance the SP mRNA levels in STZ-induced immature fetal lungs; and 2) whether maternal dex treatment and maternal STZ-DB exert their in vivo effects on SP mRNA levels by altering transcription.
METHODS

Animal model. Diabetes was induced in nonpregnant female
Sprague-Dawley rats from Charles River Laboratories (Wilmington, MA) by i.v. injection of STZ, 50 mgkg body weight (Sigma Chemical Co., St. Louis, MO) in 5 mM sodium citrate in saline, pH 4.5. Diabetes was confirmed by blood glucose determination before mating and reconfirmed before sacrifice. Only females with blood glucose more than 250 mg/dL were used for the experiments. Conditions of mating and sacrifice have been previously described (38) . Successful mating was confirmed by the presence of a copulatory plug or a vaginal smear positive for sperm on the morning after caging male and female rats together. The morning after mating occurred, is designated d 1 of gestation. Timed pregnant rats obtained from Charles River Breeding Laboratories were injected intraperitoneally with either dex (2 mglkg body weight) or equivalent volume of DMSO, 24 h before sacrifice. At the same time, pregnant STZ-DB rats were injected either with dex (2 m g k g body weight) or equivalent volume of DMSO. The dex used had a concentration of 2 mg/mL. Because our animals weighed between 250 and 350 g, 0.25-0.35 mL of either dex or DMSO was injected. The animals in all groups studied were killed 24 h later, either on d 18 or 20 of gestation, and fetuses were removed after hysterectomy. The fetal lungs were then frozen for RNA preparation. For d 18 and 20 fetuses, experiments were performed from 3 separate litters (n = 3). For d 18, two to three fetuses from each litter were pooled for each analysis generating three separate pools of fetal lungs from each litter. These three samples from each litter were run on the same blot and the average of the values obtained from these three samples were counted as one experiment (n = 1). Experiments from three litters (n = 3) were performed in this manner. For d 20 fetuses, lungs from each of the fetuses from any given litter were frozen separately. Lungs from three individual fetuses, each from a different litter (n = 3) were used for Northern analysis.
RNA preparation, blotting, and data analysis. Total lung RNA was prepared as described previously (26) . Lung tissue was homogenized in a buffer containing 4 M guanidium thiocyanate followed by centrifugation (150 000 X g ) of the homogenate through a cesium chloride cushion. The pelleted RNA was then resuspended, washed, and quantitated spectrophotometrically at A,,,, and 20-30 p g of total RNA were subjected to 1% agarose-formaldehyde gel electrophoresis. The gel-fractionated RNA was then transferred to nylon membrane (Genescreen, DuPont NEN, Boston, MA). The RNA was immobilized by cross-linking with UV light at a setting of 120 mJ in UV Stratalinker 2400 (Stratagene, La Jolla, CA). The membrane was then hybridized with 32~-labeled cDNA using 1-3 X lo5 cpm/mL (specific activity, 1 0~-1 0~ c p d p g ) . After hybridization, the membranes were washed and exposed to XAR Kodak film. The membranes were stripped in a solution containing 50% deionized formamide and 1 X SSC for 2 h at 70°C and reprobed successively with SP-A, SP-B, SP-C, and actin cDNAs. The RNA bands on the film were quantified by soft laser densitometry. For SP-A, the sums of the densitometric values of both transcripts (0.9 and 1.6 kb) were used for evaluation. The RNA level is expressed as the ratio of the densitometric value from each group hybridized to surfactant protein cDNA probe, to the densitometric value of the actin cDNA hybridization. Previously, we had shown that actin mRNA levels do not change in these models either developmentally or in response to either dex treatment (26) or diabetes (36) . Actin cDNA hybridization is, therefore, used as an internal standard.
Transcription elongation assays. Methods for the isolation of nuclei, transcription elongation (nuclear run-on) assays, and isolation of 32~-labeled RNA were essentially as described by Veletza et al. (31) . Nuclei were prepared from lungs of d 20 fetuses from control, dex-treated, and STZ-DB rats. Each transcription assay contained 2 X lo7 nuclei in 200 p L of reaction volume. Equivalent trichloroacetic acid-precipitable counts (32~-labeled RNA to similar specific activity) from each group (controls, dex treatment, STZ-DB) were hybridized at 45°C for 3-5 d to separate slot blots each containing 5 p g of linearized recombinant SP cDNAs, actin cDNA, and vector cDNA (SP65). Vector cDNA served as a negative control and actin cDNA served as a positive control. Hybridization was carried out in 46% deionized formamide, 2 X Denhart's solution, 4 X SSC, 50 mM 1,4-piperazinediethanesulfonic acid (PIPES) pH 7.0, 2 mM EDTA, pH 8.0, 0.1% SDS, and 200 pg/mL of yeast tRNA. After hybridization, filters were initially washed in 300 mM NaC1, 2 mM EDTA, 10 mM Tris, pH 7.8, for 30 min at 45"C, then 30 min at 37°C in 25 mL of 300 mM NaC1, 2 mM EDTA, Tris, pH 7.8, containing 175 p L of RNase T1 (1 X 10, U/mL) and 50 p L of RNase A (10 mg/mL). The final wash was performed for 30 min at 55°C in 300 mM NaC1, 2 mM EDTA, 10 mM Tris, pH 7.8, 0.1% SDS, and was repeated three more times. The blots from each group of each experiment were processed simultaneously and exposed to the same Kodak XAR sheet of film with intensifying screens. The intensity of each band in resulting autoradiograms was quantitated by soft laser densitometer, and the relative levels of transcription for each SP gene were determined using the actin cDNA hybridization as an internal standard, as described above. Despite our efforts to increase the intensity of the SP-B hybridization signal, this signal remained weak and difficult to reproduce by photography. We tried to increase the intensity of the SP-B hybridization by using twice the number of nuclei and two labeled nucleotides. The failure to obtain a strong SP-B hybridization may in part be accounted for by delayed SP-B expression during development (34) .
Statistical analyses. Densitometric values from Northern blots reflecting the levels of SP-A, SP-B, and SP-C mRNA were analyzed statistically after normalization to actin values. The ratios of with to without dex treatment were calculated in both groups of animals (normal and STZ-DB pregnancy). In each case, the densitometric values were derived from the same autoradiograph. In a similar manner, ratios of values obtained for STZ-DB to normal pregnancy (without dex treatment) were also calculated. All the values for mRNA levels in different groups of animals were also compared with controls (without dex treatment) = 1.00. Densitometric values from transcription elongation assays were also analyzed. The ratios of values obtained for with to without dex treatment in normal pregnancy were calculated as well as the ratios of STZ-DB to normal pregnancy (without dex treatment) were calculated and compared with corresponding ratios of mRNA levels as described for Northern blots. Statistical analysis was performed by analysis of variance with Dunnett multiple comparison test. A p value of less than 0.05 was taken to indicate a significant difference for the particular set of data.
RESULTS
Effects of maternal dex treatment on the mRNA levels of SP in fetuses of normal and STZ-DB pregnancy. Figures 1 and 2 depict the effects of maternal dex treatment on mRNA levels of SP on normal and STZ-DB pregnancy in fetal d 18 and 20, respectively. As previously reported (36, 37) , the fetal mRNA levels of SP-A, SP-B, and SP-C are decreased in STZ-DB pregnancy (lanes 7-9) compared with normal pregnancy without dex treatment (lanes 4-6). We have also reported that in vivo dex treatment enhances fetal mRNA levels of SP-A and SP-B in d 18-21 fetuses in normal pregnancy (28) . In this report, we confirm these findings for gestational age d 18 and 20 (lanes 1-6). In addition, we find that I ) mRNA levels of SP-C are enhanced in gestational d 18 and 20 (lanes 1-6) in response to maternal dex treatment; and 2) the fetal mRNA levels of SP-A, SP-B, and SP-C are enhanced in STZ-DB pregnancy within 24 h after maternal dex treatment in gestational d 18 and 20 (lanes 10-12) compared with those without dex treatment (lanes 7-9).
Quantitation of the surfactant protein mRNA levels in d 18 and 20 fetuses of normal and STZ-DB pregnancy in the presence or absence of maternal dex treatment was carried out (Fig. 3C) .
Finally, the degree to which dex enhances SP mRNA levels in normal or STZ-DB pregnancy is not significantly different (p > 0.05) between the two groups, as shown by the ratio of with to without dex treatment (Fig. 3, A and B) . Inasmuch as the initial SP mRNA levels in STZ-DB pregnancy are lower when compared with those in normal pregnancy (Figs. 3C and 4) , the absolute values of mRNA levels after dex treatment in STZ-DB pregnancy do not rise to the levels seen in normal pregnancy in either gestational d 18 or 20 (Fig 4) . The increase in SP-A mRNA levels after dex treatment in STZ-DB pregnancy were not significantly different in d 20 fetuses (Fig. 4B) . This result could be partly due to rapid developmental increase seen around gestational d 19 (36) . mRNA levels of SP genes in response to STZ-DB and maternal dex treatment are due to alteration in transcription, we performed transcription elongation (nuclear run-on) assays. These assays were done using nuclei prepared from d 20 fetal lungs. Figure 5A depicts the results of a representative transcription assay that shows decrease in transcription of SP-A and SP-C in STZ-DB compared with controls. The transcription of SP-B was also found to be decreased in STZ-DB (not shown, see "Methods"). Quantitation by densitometric analysis was car- Figure 6A is a representative transcription assay and shows that transcription of SP-A and SP-C in d 20 fetal lungs is increased after maternal dex treatment. The transcription of SP-B was also found to be increased after dex treatment (not shown, see "Methods"). The data obtained after densitometric analysis (Fig. 6B) show that the mean ? SEM for the relative enhancement of transcription of SP in response to dex treatment is 2.65 + 0.38 (n = 4) for SP-A, 2.91 + 0.62 (n = 3) for SP-B, and 1.95 + 0.46 (n = 5) for SP-C (Fig. 6B) . The Effect of maternal dex treatment and STZ-DB on fetal weight and lung weight. The effect of maternal dex (28) treatment and STZ-DB (36) on fetal weight and lung weight were similar to those seen earlier. There was a decrease in fetal and lung weights after dex treatment in normal pregnancy, as reported earlier (28) as well as in STZ-DB pregnancy compared with their respective controls. There was also a decrease in fetal and lung weight in STZ-DB compared with normal pregnancy (without dex treatment) as reported earlier (36) .
Effect of dex or STZ-DB on transcription of surfactant proteins. To determine whether the changes observed in fetal
DISCUSSION
Our results show that maternal dex treatment enhances the SP mRNA levels in the STZ-induced immature fetal lungs, suggesting that STZ-DB does not block the stimulatory effects of dex inspite of the opposite effects that STZ-DB and maternal dex have on SP mRNA levels. Although the magnitude of the dex-enhanced SP mRNA levels is similar in both groups (normal and STZ-DB pregnancy), the dex-enhanced SP mRNA levels in fetuses of STZ-DB mothers do not reach the levels seen in controls after dex treatment. Because SP mRNA levels are lower after dex treatment in STZ-DB compared with normal pregnancy, the above observation suggests that dex treatment cannot overcome the inhibitory effect that STZ-DB has on basal SP mRNA levels. These findings further suggest that some characteristic differences exist in the mechanism(s) by which these two experimental models exert their effects on SP gene expression. Infants born to uncontrolled diabetic mothers are at increased risk for developing RDS (13-15) compared with their normal counterparts. Because SP-A (16, 17) is found to be reduced in amniotic fluid of pregnant diabetic women, it is possible that careful administration of dex to diabetic mothers before parturition could enhance expression of SP-A, and of other SP. These changes in turn may contribute to a reduction in the incidence of RDS in infants born to these mothers.
We detected SP-A, SP-B, and SP-C mRNA in d 18 rat fetuses, which is consistent with results obtained earlier in our laboratory (28, 36, 37) but in contrast to findings of Schellhase et al. (29, 34) (28, 29) . It is possible that as the levels of SP mRNA increase with advancing gestational age (28, 34) , dex treatment in the late stages of gestation has a limited role in enhancing SP mRNA levels. The dex-induced increase in SP-C mRNA, on the other hand, was smaller than that in SP-A and SP-B mRNA, and there was no significant difference in the degree of enhancement of SP-C mRNA between d 18 and 20 rat fetuses. These results may be explained by the earlier appearance of SP-C mRNA during fetal development compared with SP-A and SP-B mRNA (34) . However, it is also likely that SP-C is involved in other important developmental functions and therefore, it may be regulated differently from SP-A and SP-B.
Several factors, including insulin and glucose, have been implicated in the inhibition of SP synthesis and SP mRNA levels in vitro (40, 41) . Uncontrolled diabetic pregnancy in humans is accompanied by fetal hyperglycemia and hyperinsulinemia. The STZ-DB model used here, exhibits fetal hyperglycemia with normal to low plasma insulin levels (38, 42) , suggesting that hyperglycemia has an important role in inhibiting SP mRNA levels in vivo. In this regard, high glucose (50-100 mM) but not insulin (1UImL) delayed fetal lung development in d 20 fetal rat lung explants as determined by reduced incorporation of 3~ into phosphatidylcholine and disaturated phosphatidylcholine (43) . Furthermore, fetal lung phosphatidylcholine and disaturated phosphatidylcholine were increased to normal level in STZ-DB in d 21 and 22 rat fetuses by dex treatment, suggesting that delayed fetal lung maturation seen in STZ-DB could be reversed by dex (44) . The levels of SP mRNAs were not examined in either of these studies (43, 44) . Thus, hyperglycemia appears to be one of the factors involved in the regulation of lung maturationlfetal surfactant protein gene expression in STZ-DB pregnancy. In adult rats, the effect of the STZ-DB state on SP-A and SP-B (but not SP-C) mRNA levels (45, 46) is different from that observed in the fetal lung (36) suggesting that different mechanisms are operative in the regulation of SP expression in STZ-induced immature fetal lung and adult STZ-DB rats.
Transcription of all three SP is reduced in STZ-DB and enhanced by dex treatment in lungs of d 20 fetuses. This is the first in vivo demonstration that a transcriptional step is involved in the regulation of surfactant protein gene expression in response to STZ-induced diabetes. However, the degree of inhibition of transcription among the three SP in STZ-DB differs, being highest for SP-A and lowest for SP-C. The degree of inhibition of transcription of SP-C in fetuses of STZ-DB compared with control corresponds well with reduction in their mRNA levels (Fig. 4B) . It seems likely that the regulatory control for SP-C mRNA occurs primarily at the transcriptional level in the STZ-DB model. In contrast, inhibition of transcription of SP-A and SP-B in STZ-DB is significantly greater (p < 0.05) than the decrease observed in their corresponding mRNA levels (Fig. 4B) , suggesting that in addition to a transcriptional control, posttranscriptional mechanism(~) are involved in SP-A and SP-B gene expression in the STZ-DB model. It is possible that reduction in the transcription of SP-A and SP-B is partially offset by an increase in mRNA stability. In this regard, Na butyrate has been shown to reduce SP-A and SP-B mRNA levels by affecting both transcription and mRNA stability, in explant rat lung cultures (47) . Whether butyric acid analogs as P-hydroxybutyrate that is increased in diabetes can mediate the reduction in SP mRNAs observed in fetuses of STZ-DB pregnancy remains to be determined. Furthermore, the stability of several mRNAs is shown to increase in the presence of a transcription blocking drug. For example, actinomycin D increases transferrin receptor mRNA stability more than 10-fold (48) . In this regard, the stability of SP-B mRNA in a human pulmonary adenocarcinoma cell line, NCI-H441-4 cells is increased after actinomycin D treatment in the presence or absence of glucocorticoids (49) . Additionally, in the same system, the inhibitory effects of TNF-a and TPA on SP-A and SP-B mRNA levels are blocked by actinomycin D (50) . Whether STZ-DB acts similar to actinomycin D and affects transcription of factors involved in mRNA stability of SP-A and SP-B is currently unknown. Moreover, the SP-B mRNA levels were markedly reduced in NCI-H441-4 cell line after exposure to puromycin, an inhibitor of protein synthesis. Whether continuous protein synthesis is required for the stability of SP message in vivo is unknown.
The degree of increase in transcription of SP-A and SP-B in response to in vivo dex treatment may only partially account for the total content of SP-A and SP-B mRNA levels observed. The increase in the rate of transcription for SP-A and SP-B at gestational d 20 is 68 and 60%, respectively, of the observed increase in the SP-A and SP-B mRNA levels. This observation suggests a role of posttranscriptional mechanism(s) in the regulation of SP-A and SP-B mRNA levels. Alternatively, the differences observed between transcription and mRNA content could be due to an accumulative effect as a result of increased synthesis with no change in the rate of mRNA degradation. However, previous in vitro studies in NCI-H441-4 cell culture system have shown that the dex-enhanced transcription of SP-B is only partially responsible for the increase in their mRNA levels (49) and in human fetal lung explants, glucocorticoids regulate SP-A (5 1) and SP-B (52) expression by affecting transcription as well as mRNA stability. In contrast to SP-A and SP-B, we found that the difference between changes in mRNA levels of SP-C and its transcription in response to dex treatment is not significantly different. These results are also consistent with in vitro findings in fetal rat lung explants where no significant differences between SP-C transcription and SP-C mRNA levels in response to dex treatment were detected (31) . Moreover, Venkatesh et al. 1993 (52) found that enhancement of SP-C mRNA in response to glucocorticoids involves increased transcription without a change in mRNA stability in human fetal lung explants. Together these observations indicate that posttranscriptional mechanisms may not have any significant role in regulation of SP-C mRNA levels. This finding also suggests that SP-C mRNA is regulated differently from SP-A and SP-B mRNA in this respect.
In conclusion, we show that maternal dex treatment enhances SP mRNA levels in the STZ-induced immature fetal lungs suggesting that STZ-DB pregnancy does not prevent the stimulatory effects of dex on SP mRNA levels. Maternal dex treatment, however, does not appear to overcome the basal inhibition by STZ-DB. Furthermore, the changes seen in SP-A and SP-B mRNA levels in response to dex or STZ-DB are at least in part due to alteration in transcription of SP genes. The effect of dex or STZ-DB on SP-C mRNA appears to involve primarily a transcriptional control.
